



[www.medsurge.com.au](http://www.medsurge.com.au)  
ABN 92 124 728 892



AstraZeneca Pty Ltd  
Alma Rd  
North Ryde, NSW 2113  
T: +61 (0)2 9978 3500  
F: +61 (0)2 9978 3700  
[astrazeneca.com.au](http://astrazeneca.com.au)

27 March, 2015

Dear Healthcare Professional,

**Succinolin® (Suxamethonii hydrochloridum anhydricum) Injection 100 mg/2mL ampoule**

Medsurge and AstraZeneca recognise the importance of supplying emergency medicines in Australia and would like to advise you of a change in supply status of Suxamethonium Chloride Injection 100mg/2mL ampoule in Australia.

As you are aware the Australian registered product, Suxamethonium Chloride 100mg/2mL injection BP ampoule AUST R11988 is currently affected by a supply shortage due to a manufacturing issue. Medsurge has been able to arrange for supply of an alternative product **Succinolin®** (Suxamethonii hydrochloridum anhydricum) Injection 100mg/2mL ampoule on a temporary basis, which has similar indications to the Australian registered product. **Succinolin®** (Suxamethonii hydrochloridum anhydricum) Injection 100mg/2mL ampoule is not registered in Australia and it will be supplied under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989.

**Succinolin®** (Suxamethonii hydrochloridum anhydricum) Injection 100mg/2mL ampoule is registered and marketed in Switzerland by Amino AG and therefore all labelling is in German.

It should be noted that the package label states brand name and active ingredient as being **Succinolin®** (Suxamethonii hydrochloridum anhydricum) Injection 100mg/2mL ampoule, however the active ingredient is **Suxamethonium chloride anhydrous**.

**This product contains 10% more suxamethonium than the registered product. The volume injected will need to be adjusted to provide equivalent doses to your patients.**

Please refer to below table for equivalent dosing.

|                     | <b>Australian Registered Product</b>  | <b>S19A Product</b>   |
|---------------------|---|---|
| <b>Label</b>        | AstraZeneca Suxamethonium Chloride Injection 100mg/2mL ampoule (AUST R 11988) | Succinolin® (Suxamethonii hydrochloridum anhydricum) Injection 100 mg/2mL ampoule |
| <b>Presentation</b> | Polyamp DuoFit ampoules 100mg/2mL in packs of 50                              | Ampoules 100mg/2mL packs of 10 and 100  |



[www.medsurge.com.au](http://www.medsurge.com.au)  
ABN 92 124 728 892



AstraZeneca Pty Ltd  
Alma Rd  
North Ryde, NSW 2113  
T: +61 (0)2 9978 3500  
F: +61 (0)2 9978 3700  
[astrazeneca.com.au](http://astrazeneca.com.au)

|                                  | Australian Registered Product   | S19A Product  |
|----------------------------------|---|---|
| <b>Dosage and administration</b> | 100mg in 2mL<br>Refer to the Australian registered product approved PI (included) | 100mg in 2mL<br>suxamethonium chloride anhydrous ( <b>equivalent to 110mg in 2mL of suxamethonium chloride</b> )<br>Refer to the Australian registered product approved PI (included) |

The TGA recommends that the HealthCare Professional refer to the AstraZeneca Suxamethonium Chloride 100mg/2mL injection BP ampoule Product Information (PI) attached to the letter before prescribing or dispensing of this product.

*If you wish to order this product, please contact Medsurge Healthcare on 1300 788 261 or email [sales@medsurge.com.au](mailto:sales@medsurge.com.au).*

Any adverse events which are experienced with **Succinolin**<sup>®</sup> (Suxamethonii chloridum anhydricum) Injection 100mg/2mL ampoule should be reported by healthcare professionals, pharmacists and patients to the TGA or Medsurge on 1300 788 261 or email [sales@medsurge.com.au](mailto:sales@medsurge.com.au).

Any product complaints with **Succinolin**<sup>®</sup> (Suxamethonii chloridum anhydricum) Injection 100mg/2mL ampoule should be reported to Medsurge on 1300 788 261 or email [sales@medsurge.com.au](mailto:sales@medsurge.com.au).

Please ensure this information is forwarded to relevant staff members in your organisation.

AstraZeneca continues to anticipate that we will be in a position to recommence supply of AstraZeneca branded suxamethonium chloride injection by the end of April. We will communicate again with you when normal supply arrangements of AstraZeneca's product has resumed.

We are pleased to announce this arrangement and wish to thank you for your continued patience and understanding during this disruption to the supply of suxamethonium chloride injection.

For further information, please contact Medsurge Healthcare on 1300 788 261 or email [sales@medsurge.com.au](mailto:sales@medsurge.com.au).

Yours Sincerely,

Sonja Cuce  
Regulatory Manager - Medsurge Healthcare

Dr Paul Bennett  
Acting Medical Director - AstraZeneca Australia